In in vitro experiments, binding of nimotuzumab and subsequent inhibition of the EGFR phosphorylation was detected only for tumor cell lines with medium or high levels of EGFR expression (104 receptors per cell or higher). The gene discussed is EGFR; the disease is neoplasm.